Asthma treatment

71. AFX Asia Focus – May 21, 2008 AFX Asia (Focus): GlaxoSmithKline: No increase in cardiac events in patients treated with Advair SAN FRANCISCO (Thomson Financial) – GlaxoSmithKline said Wednesday that a three-year study of chronic obstructive pulmonary disease found that patients being treated with Advair Diskus 500/50 experienced the fewest adverse cardiac events compared with patients taking other treatments or a placebo. The data was part of the TOwards a Revolution in COPD Health study of 6, 000 patients that was presented at the International Conference of the American Thoracic Society meeting in Toronto ….. (TX) – April 18, 2007 Fee for asthma drug to rise Advair, the popular twice-a-day drug that many asthma sufferers rely on to control the disease, soon will get more expensive for UnitedHealthcare members. The health insurer plans to begin charging higher co-payments for the medicine May 1, effectively doubling consumers’ out-of-pocket expense to about $50. At the same time, the price of several other asthma drugs that UnitedHealthcare is promoting as “first-line treatments” will fall to $10. The ….. (TX) – April 18, 2007 Fee for asthma drug to rise Advair, the popular twice-a-day drug that many asthma sufferers rely on to control the disease, soon will get more expensive for UnitedHealthcare members. The health insurer plans to begin charging higher co-payments for the medicine May 1, effectively doubling consumers’ out-of-pocket expense to about $50. At the same time, the price of several other asthma drugs that UnitedHealthcare is promoting as “first-line treatments” will fall to $10. The ….. (TX) – April 18, 2007 Fee for asthma drug to rise Advair, the popular twice-a-day drug that many asthma sufferers rely on to control the disease, soon will get more expensive for UnitedHealthcare members. The health insurer plans to begin charging higher co-payments for the medicine May 1, effectively doubling consumers’ out-of-pocket expense to about $50. At the same time, the price of several other asthma drugs that UnitedHealthcare is promoting as “first-line treatments” will fall to $10. The ….. (TX) – April 18, 2007 Fee for asthma drug to rise Advair, the popular twice-a-day drug that many asthma sufferers rely on to control the disease, soon will get more expensive for UnitedHealthcare members. The health insurer plans to begin charging higher co-payments for the medicine May 1, effectively doubling consumers’ out-of-pocket expense to about $50. At the same time, the price of several other asthma drugs that UnitedHealthcare is promoting as “first-line treatments” will fall to $10. The ….. China Post (Taiwan) – November 25, 2005 China Post: FDA plans to restrict Advair asthma treatment A Hong Kong based newspaper reported yesterday that the U. S. Food and Drug Administration (FDA) has announced plans to restrict the use of Advair, the best-selling asthma treatment from one of Europe’s largest drug company GlaxoSmithKline (GSK). The FDA declared that Advair, which is sold as Seretide in Europe, should not be given as a first-line treatment unless other medicines had failed to control asthma. Seretide, along with Serevent and Oxis — two other types of asthma ….. – October 24, 2001 New drugs raise quarter gains Advair, Serevent and Flovent help GlaxoSmithKline’s profit jump 19% Pharmaceutical giant GlaxoSmithKline’s profit rose 19 percent to $1. 4 billion for the third quarter on the strength of new products like asthma drug Advair, the company reported Tuesday. Company CEO Jean-Pierre Garnier said GlaxoSmithKline’s strong results for the quarter indicate that the company is on track to have earnings per share growth around 13 percent for the year. The sales of respiratory products, including Advair, Serevent and Flovent grew 53 percent ….. Knight-Ridder/Tribune Business News – October 24, 2001 Advair, Serevent and Flovent Help GlaxoSmithKline’s Profit Jump 19 Percent Oct. 24–Pharmaceutical giant GlaxoSmithKline’s profit rose 19 percent to $1. 4 billion for the third quarter on the strength of new products like asthma drug Advair, the company reported Tuesday. Company CEO Jean-Pierre Garnier said GlaxoSmithKline’s strong results for the quarter indicate that the company is on track to have earnings per share growth around 13 percent for the year. The sales of respiratory products, including Advair, Serevent and Flovent grew 53 ….. (TX) – April 18, 2007 Fee for asthma drug to rise Apr. 18–Advair, the popular twice-a-day drug that many asthma sufferers rely on to control the disease, soon will get more expensive for UnitedHealthcare members. The health insurer plans to begin charging higher co-payments for the medicine May 1, effectively doubling consumers’ out-of-pocket expense to about $50. At the same time, the price of several other asthma drugs that UnitedHealthcare is promoting as “first-line treatments” will fall to ….. Guardian, The (London, England) – November 22, 2005 The Guardian: Financial: US ruling on Glaxo asthma drug wipes billions off value: FDA says Advair should be prescribed as a last resort: Shares slide 4% on fears for GSK’s biggest seller Investors savaged the GlaxoSmithKline share price yesterday, wiping almost 4% off the drugs group’s value as the market reacted to a ruling in the United States on how the company should label its best-selling asthma drug. The US food and drug administration (FDA) recommended late on Friday that Glaxo’s Advair asthma treatment – an inhaled steroid that is sold as Seretide in Europe – should be re-labelled to make it clear that the drug should only be prescribed for ….